DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20221822

The effectiveness of dapsone as refracterial therapy for juvenile dermatomyositis

Prayogi Miura Susanto

Abstract


Juvenile dermatomyositis (JDM) is a rare autoimmune disease that affects mostly children's muscles and skin. The small number of patients with JDM, heterogeneous disease phenotype, and few clinical trials for JDM pose challenges for clinicians in developing standard treatment protocols. Although there has been some consensus, the obstacles to JDM therapy, especially in refractory cases, have not been resolved. Dapsone is one of the anti-inflammatory agents that can provide significant clinical improvement in patients with dermatomyositis. This aim of the study was to discuss various previous studies to determine the potential use of dapsone in cases of refractory JDM.


Keywords


Dapsone, Juvenile dermatomyositis, Idiopathic inflammatory myopathy, Refractory

Full Text:

PDF

References


Pilkington CA, Feldman BM, Sontichai W. Juvenile dermatomyositis and other inflammatory muscle diseases. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, Mellins ED, Fuhlbrigge RC, eds. Textbook of Pediatric Rheumatology. 8th ed. Philadelphia: Elsevier; 2021.

Gara S, Jamil RT, Muse ME, et al. Juvenile Dermatomyositis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK534236/. Accessed on 25 January 2022.

Kim H, Huber AM, Kim S. Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes. Rheum Dis Clin North Am. 2021;47(4):669-90.

Wienke J, Deakin CT, Wedderburn LR, Wijk F, Royen-Kerkhof A. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. Front Immunol. 2018;9:2951.

Pachman LM, Khojah AM. Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. J Pediatr. 2018;195:16-27.

Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329-40.

Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, Pilkington CA, et al. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22(1):79.

Cinar O, Papadopoulou C, Pilkington CA. Treatment of Calcinosis in Juvenile Dermatomyositis. Curr Rheumatol Rep. 2021;23(2):13.

Wane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267-81.

Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: Latest advances. Best Pract Res Clin Rheumatol. 2017;31(4):535-57.

Lahoria R, Selcen D, Engel AG. Microvascular alterations and the role of complement in dermatomyositis. Brain. 2016;139(7):1891-903.

Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-7.

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-7.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955-64.

Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2020;16(1):31-43.

Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671-8.

Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089-94.

Dagher R, Desjonquères M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711-6.

Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, et al. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis Rheumatol. 2018;70(5):785-93.

Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15(1):1.

Hassan J, Net JJ, Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27(11):1469-71.

Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014;66(5):783-7.

Sukumaran S, Vijayan V. Abatacept in the Treatment of Juvenile Dermatomyositis-Associated Calcifications in a 16-Year-Old Girl. Case Rep Rheumatol. 2020;2020:4073879.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314-24.

Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406-8.

Zhang Y, Milojevic D. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations. Paediatr Drugs. 2017;19(3):193-211.

Habers GE, Bos GJ, Kerkhof A, Lelieveld OT, Armbrust W, Takken T, et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatology (Oxford). 2016;55(7):1251-62.

Berntsen KS, Tollisen A, Schwartz T, Kirkhus E, Aaløkken TM, Lund MB, et al. Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement. J Rheumatol. 2017;44(6):827-34.

Cohen JB. Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. Int J Dermatol. 2002;41(3):182-4.

Kurian G, Jamil RT, Preuss CV. Dapsone. Treasure Island, FL: StatPearls Publishing; 2022.

Ghaoui N, Hanna E, Abbas O, Kibbi AG, Kurban M. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59(7):787-95.

Goh CL, Pan JY. Dapsone. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al, eds. Fitzpatrick’s Dermatology. 9th ed. New York: McGraw-Hill Education; 2019.

Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103-24.

Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994;19(4):367.

Galrão LDA, Reale J, Lima I, Santiago M. Efficacy of dapsone in two cases of amyopathic dermatomyositis. Anais Brasileiros de Dermatologia. 2006;81(2):181-2.

Macêdo PA, Garcia CB, Schmitz MK, Jales LH, Pereira RM, Carvalho JF. Juvenile systemic lupus erythematosus and dermatomyositis associated with urticarial vasculitis syndrome: a unique presentation. Rheumatol Int. 2012;32(11):3643-6.

Kawachi Y, Fujisawa Y, Furuta J, Nakamura Y, Ishii Y, Otsuka F. Pruritic poikilodermatous eruption associated with dermatomyositis: successful treatment with dapsone. Eur J Dermatol. 2012;22(2):289-90.

Ishibuchi H, Motegi S, Amano H, Ishikawa O. Successful treatment with dapsone for skin lesions of amyopathic dermatomyositis. J Dermatol. 2015;42(10):1019-21.

Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother. 2004;5(5):1083-99.